ScreenPoint Medical

Executive Summary

ScreenPoint Medical, founded in 2012 and headquartered in Nijmegen, Netherlands, is a pioneer in AI-powered breast imaging. Its flagship product, Transpara Breast AI, is FDA-cleared and CE-marked, assisting radiologists in detecting breast cancer from both 2D and 3D mammograms. The software leverages deep learning to improve diagnostic accuracy and streamline radiologist workflow, addressing the growing need for efficient screening solutions. With a strong regulatory foundation and commercial traction, ScreenPoint is well-positioned for growth. The company continues to innovate, exploring expansions into new imaging modalities and international markets. However, competition from established medtech firms and AI startups remains intense. Overall, ScreenPoint's validated technology and regulatory approvals provide a solid basis for sustained market penetration, though execution risks persist.

Upcoming Catalysts (preview)

• Q3 2026CE mark under EU MDR for Transpara Breast AI80% success
• Q2 2026Publication of results from large-scale multi-site clinical study70% success
• Q4 2026Strategic partnership with leading mammography OEM for global distribution60% success